Free Trial

Bon Natural Life (BON) Competitors

Bon Natural Life logo
$2.10 +0.70 (+50.00%)
Closing price 05/22/2025 04:00 PM Eastern
Extended Trading
$1.86 -0.24 (-11.29%)
As of 08:17 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BON vs. FNCH, SLGL, OVID, QTTB, LGVN, NAII, CGTX, DRRX, ELEV, and CMMB

Should you be buying Bon Natural Life stock or one of its competitors? The main competitors of Bon Natural Life include Finch Therapeutics Group (FNCH), Sol-Gel Technologies (SLGL), Ovid Therapeutics (OVID), Q32 Bio (QTTB), Longeveron (LGVN), Natural Alternatives International (NAII), Cognition Therapeutics (CGTX), DURECT (DRRX), Elevation Oncology (ELEV), and Chemomab Therapeutics (CMMB). These companies are all part of the "pharmaceutical products" industry.

Bon Natural Life vs.

Finch Therapeutics Group (NASDAQ:FNCH) and Bon Natural Life (NYSE:BON) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, community ranking, media sentiment, valuation and institutional ownership.

Finch Therapeutics Group received 10 more outperform votes than Bon Natural Life when rated by MarketBeat users.

CompanyUnderperformOutperform
Finch Therapeutics GroupOutperform Votes
10
52.63%
Underperform Votes
9
47.37%
Bon Natural LifeN/AN/A

In the previous week, Bon Natural Life had 4 more articles in the media than Finch Therapeutics Group. MarketBeat recorded 4 mentions for Bon Natural Life and 0 mentions for Finch Therapeutics Group. Bon Natural Life's average media sentiment score of 0.67 beat Finch Therapeutics Group's score of 0.00 indicating that Bon Natural Life is being referred to more favorably in the news media.

Company Overall Sentiment
Finch Therapeutics Group Neutral
Bon Natural Life Positive

Finch Therapeutics Group has a beta of 1.27, suggesting that its share price is 27% more volatile than the S&P 500. Comparatively, Bon Natural Life has a beta of -0.47, suggesting that its share price is 147% less volatile than the S&P 500.

Bon Natural Life's return on equity of 0.00% beat Finch Therapeutics Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Finch Therapeutics GroupN/A -69.14% -26.92%
Bon Natural Life N/A N/A N/A

21.8% of Finch Therapeutics Group shares are owned by institutional investors. Comparatively, 0.6% of Bon Natural Life shares are owned by institutional investors. 44.9% of Finch Therapeutics Group shares are owned by company insiders. Comparatively, 26.5% of Bon Natural Life shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Bon Natural Life has higher revenue and earnings than Finch Therapeutics Group.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Finch Therapeutics Group$110K189.80-$74.75M-$8.82-1.47
Bon Natural Life$23.84M0.01$400KN/AN/A

Summary

Bon Natural Life beats Finch Therapeutics Group on 6 of the 11 factors compared between the two stocks.

Get Bon Natural Life News Delivered to You Automatically

Sign up to receive the latest news and ratings for BON and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BON vs. The Competition

MetricBon Natural LifeMedicinals & botanicals IndustryDiscretionary SectorNYSE Exchange
Market Cap$351,000.00$1.19B$7.86B$19.29B
Dividend YieldN/AN/A3.25%3.83%
P/E RatioN/A11.1615.1134.52
Price / Sales0.018.428.0134.82
Price / Cash0.7810.4016.3717.51
Price / Book0.061.514.774.69
Net Income$400,000.00-$56.07M$257.85M$1.02B
7 Day Performance31.66%2.66%-1.44%-2.43%
1 Month Performance43.59%10.79%6.47%6.27%
1 Year Performance-97.13%-33.73%-1.86%5.78%

Bon Natural Life Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BON
Bon Natural Life
N/A$2.10
+50.0%
N/A-97.3%$351,000.00$23.84M0.00100News Coverage
Gap Up
High Trading Volume
FNCH
Finch Therapeutics Group
N/A$13.48
+1.7%
N/A+510.3%$21.65M$110,000.00-1.53190Gap Down
SLGL
Sol-Gel Technologies
2.1542 of 5 stars
$7.72
+3.3%
$50.00
+547.7%
-2.7%$21.51M$11.54M-22.7150News Coverage
OVID
Ovid Therapeutics
4.1688 of 5 stars
$0.30
-0.6%
$3.03
+907.4%
-91.1%$21.41M$548,000.00-0.6460Gap Up
QTTB
Q32 Bio
2.1024 of 5 stars
$1.74
-1.7%
$24.71
+1,320.4%
-94.5%$21.23M$-6,651,000.00-0.1239
LGVN
Longeveron
3.2579 of 5 stars
$1.40
-1.4%
$8.67
+519.0%
+18.5%$20.90M$2.23M-0.2220News Coverage
Analyst Revision
NAII
Natural Alternatives International
0.5454 of 5 stars
$3.31
+1.8%
N/A-49.4%$20.52M$121.85M-2.57290Analyst Forecast
Gap Up
CGTX
Cognition Therapeutics
2.5281 of 5 stars
$0.33
+1.5%
$6.13
+1,756.1%
-88.0%$20.46MN/A-0.3420
DRRX
DURECT
0.1802 of 5 stars
$0.65
+3.1%
N/A-55.8%$20.17M$2.03M-1.0780News Coverage
Analyst Forecast
Gap Down
High Trading Volume
ELEV
Elevation Oncology
2.9034 of 5 stars
$0.34
+20.4%
$3.39
+895.8%
-91.6%$20.14MN/A-0.4140Negative News
CMMB
Chemomab Therapeutics
3.3008 of 5 stars
$1.39
+1.5%
$8.50
+511.5%
+61.9%$19.96MN/A-1.3920

Related Companies and Tools


This page (NYSE:BON) was last updated on 5/23/2025 by MarketBeat.com Staff
From Our Partners